Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Schliemann

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
Blood|March 19, 2026
A WHIM of the marrow: myelokathexis as a cytological clue to a rare blood disorderAkhil Behringer, Christoph Schliemann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 25, 2009
Antibody-based vascular tumor targetingChristoph Schliemann, Dario Neri
Biochimica Et Biophysica Acta|October 9, 2007
Antibody-based targeting of the tumor vasculatureChristoph Schliemann, Dario Neri
Blood|January 17, 2017
Folding two lobes, you don't get a cup?Jan-Henrik Mikesch, Christoph Schliemann
Cancer Treatment Reviews|May 23, 2022
Emerging antibody-based therapies for the treatment of acute myeloid leukemiaLinus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann
Journal of Mass Spectrometry : JMS|March 5, 2019
Are formalin-fixed and paraffin-embedded tissues fit for proteomic analysis?Malte Bayer, Linus Angenendt, Christoph Schliemann, et al.
The Journal of Urology|October 30, 2010
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinomaKatharina Frey, Christoph Schliemann, Kathrin Schwager, et al.
Journal of Proteomics|January 26, 2011
The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosisChristoph Roesli, Tim Fugmann, Beatrice Borgia, et al.
Leukemia Research|July 24, 2009
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphomaChristoph Schliemann, Andrea Wiedmer, Marta Pedretti, et al.
Blood|November 12, 2009
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapyChristoph Schliemann, Christoph Roesli, Haruhiko Kamada, et al.
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
Blood|March 19, 2026
A WHIM of the marrow: myelokathexis as a cytological clue to a rare blood disorderAkhil Behringer, Christoph Schliemann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 25, 2009
Antibody-based vascular tumor targetingChristoph Schliemann, Dario Neri
Biochimica Et Biophysica Acta|October 9, 2007
Antibody-based targeting of the tumor vasculatureChristoph Schliemann, Dario Neri
Blood|January 17, 2017
Folding two lobes, you don't get a cup?Jan-Henrik Mikesch, Christoph Schliemann
Cancer Treatment Reviews|May 23, 2022
Emerging antibody-based therapies for the treatment of acute myeloid leukemiaLinus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann
Journal of Mass Spectrometry : JMS|March 5, 2019
Are formalin-fixed and paraffin-embedded tissues fit for proteomic analysis?Malte Bayer, Linus Angenendt, Christoph Schliemann, et al.
The Journal of Urology|October 30, 2010
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinomaKatharina Frey, Christoph Schliemann, Kathrin Schwager, et al.
Journal of Proteomics|January 26, 2011
The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosisChristoph Roesli, Tim Fugmann, Beatrice Borgia, et al.
Leukemia Research|July 24, 2009
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphomaChristoph Schliemann, Andrea Wiedmer, Marta Pedretti, et al.
Blood|November 12, 2009
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapyChristoph Schliemann, Christoph Roesli, Haruhiko Kamada, et al.
Pageof 17